Cases Of African Tick-bite Fever Research Articles

A Case of African Tick-Bite Fever in a Returning Traveler from Southern Africa

African tick-bite fever (ATBF), caused by Rickettsia africae, is the second most frequent cause of fever after malaria in travelers returning from Southern Africa. As the Korean outbound travelers are increasing every year, tick-borne rickettsial diseases as a cause of febrile illness are likely to increase. We describe a febrile Korean returning traveler who showed two eschars after visiting the rural field in Manzini, Swaziland. We performed nested polymerase chain reaction using the eschar and diagnosed the patient with ATBF. He was treated with oral doxycycline for 7 days, and recovered without any complications. We believe that the present case is the first ATBF case diagnosed in a Korean traveler.

A case of African tick-bite fever in a returning traveler

A case of African tick-bite fever in a returning traveler

Rickettsia africaeInfection in Man after Travel to Ethiopia

To the Editor: The first human case of African tick-bite fever was described in 1992 as occurring in Zimbabwe. The causative agent was identified as a new serotype of the spotted fever group (SFG) rickettsiae and named Rickettsia africae (1). These findings confirmed observations made by Pijper in the 1930s, which suggested that there were 2 different kinds of human SFG rickettsioses in sub-Saharan Africa: Mediterranean spotted fever caused by R. conorii and transmitted by Rhipicephalus species, ticks of dogs, and African tick-bite fever caused by R. africae and transmitted by Amblyomma species, ticks of cattle and wild ungulates. African tick-bite fever has subsequently been diagnosed in patients from several other sub-Saharan countries and also from the West Indies (2,3). In a recent analysis of the spectrum of diseases among returning travelers, tick-borne spotted fever was (after malaria) the second most frequent cause of systemic febrile illness among those returning from sub-Saharan Africa. It occurred more frequently than typhoid fever and dengue fever (4). The following case description reports an infection with R. africae in a man in France who recently returned from Ethiopia. On November 4, 2005, a 62-year-old French man sought care at the Medical Center of the Institut Pasteur in Paris for fever, along with chills, headache, neck and shoulder pain, and fatigue over the previous 4 days. At the onset of these symptoms he had noticed dark nodular lesions on his neck and his left groin followed 2 days later by a slightly painful eruption on his arms and his trunk. He had spent a month in southwest Ethiopia, north of Kelem near the Sudanese border, and returned to France on October 26, 2005. While in Ethiopia, he had assisted with a production of a documentary film about an Ethiopian tribe and had been in contact with cattle in the villages. He had not noticed any tick bites. On physical examination he had a fever of 38°C, a nodular lesion with a central dark crust on his neck, a second lesion on his left inguinal fold (Figure, panel A), and a vesicular eruption on his arms and his trunk (Figure, panel B). Leukocyte count was 3,200, including 1,869 neutrophils and 867 lymphocytes. The platelet level was 174,000/mm3. The C-reactive protein level was 28.3 mg/L. The aspartate aminotransferase level was slightly elevated. The patient was treated with doxycycline 200 mg/day for 1 week for suspected African tick-bite fever. Follow-up showed a quick recovery from his symptoms except for fatigue that persisted for ≈1 month. Figure Inoculation eschar on left inguinal fold (A) and vesicular skin lesion (B) in a traveler recently returned to France from Ethiopia. A commercial immunofluorescence assay for R. conorii and R. typhi immunoglobulin G performed both on an initial blood sample and a second sample taken 1 week later were negative. A blood sample and a biopsy specimen of the inguinal eschar were sent to the National Reference Center of Rickettsiae in Marseille, France. Although cellular culture of both specimens and molecular testing of the blood sample were negative, PCR for the sequences of citrate synthase (GenBank accession no. {type:entrez-nucleotide,attrs:{text:RAU59733,term_id:1389980}}RAU59733, 93.1% homology) and rickettsial OmpA (GenBank accession no. {type:entrez-nucleotide,attrs:{text:RAU83436,term_id:62861416}}RAU83436, 99.3% homology) applied on the skin biopsy detected R. africae and confirmed the diagnosis of African tick-bite fever. From 1969 to 1971, SFG rickettsiae were isolated from Amblyomma spp. ticks collected in Ethiopia. They were regarded as R. conorii or as closely related bacteria (5). Later, more specific tests using western immunoblots with monoclonal antibodies showed that these rickettsiae differed from R. conorii (6). In 1992 SFG rickettsiae isolated from Amblyomma ticks collected in Zimbabwe and from the blood of a patient in Zimbabwe were compared to R. conorii, to other pathogenic SFG rickettsiae, and to a SFG rickettsia isolated from an Amblyomma spp. tick in Ethiopia 20 years before. The SFG rickettsia isolates from Ethiopia were identical to isolates obtained in Zimbabwe from the Amblyomma ticks and the patient’s blood and were different from R. conorii and other pathogenic SFG rickettsiae. This new serotype of SFG rickettsiae was named R. africae (1,7). A recent study confirmed the presence of R. africae in ticks collected in Ethiopia, as well as R. aeschlimanii (8). Thus, evidence of R. africae in Ethiopia has been known for a long time. The geographic distribution of African tick-bite fever is related to the presence of Amblyomma spp. ticks, vectors and reservoirs of R. africae. Consequently African tick-bite fever should also be considered as a possible diagnosis in patients with febrile illness returning from countries where R. africae has been detected in Amblyomma ticks, even if a human infection has not yet been reported (9,10).

African Tick-bite Fever: Four Cases Among Swiss Travelers Returning from South Africa

African tick-bite fever (ATBF) is a recently described disease belonging to the spotted fever group. It is caused by Rickettsia africae, and cases are mainly diagnosed in travelers returning from sub-Saharan Africa. We report four cases of ATBF among Swiss travelers returning from a 1-month trip in rural South Africa. Diagnosis was made on the basis of clinical, epidemiologic and serologic findings that we describe in detail. Serology was performed using microimmunofluorescence (MIF) assay 2 weeks, 6 weeks and 14 months after the commencement of symptoms. All patients developed the typical eschar and a rash; two had a local lymphadenopathy and one a lymphangitic reaction. Two patients developed transient neuropsychiatric symptoms such as headache, irritability and depressed mood. All four patients had rises in both IgM and IgG classes of anti-R. africae antibodies. After 1 year, only two patients still had measurable circulating antibodies. Cross-reactions with R. conorii were noted. Three patients were cured after a short course of doxycycline; one required 15 days of treatment. ATBF is a benign disease increasingly being diagnosed in travelers. After ruling out malaria, ATBF diagnosis relies upon a detailed travel history and the classical findings of influenza-like symptoms, fever, one or more necrotic eschars, and rash. Serologic tests usually help to confirm the diagnosis. Neuropsychiatric symptoms specifically associated with ATBF are reported here for the first time.

African Tick-bite Fever in French Travelers

To the Editor: African tick-bite fever (ATBF) is caused by Rickettsia africae and remains the most common tickborne rickettsiosis in sub-Saharan Africa (1,2). We describe an outbreak of ATBF in 10 of 34 French tourists on their return from South Africa in March 2005. Fever, skin rash, and multiple eschars on the legs developed in the index case-patient (patient 9, Table). After informed consent was obtained, the tourists completed a questionnaire for epidemiologic and clinical data. Acute- and convalescent-phase serum samples were collected when possible for serologic analysis performed at the Unite des Rickettsies. The samples were tested against a panel of antigens including R. typhi, Francisella tularensis, Coxiella burnetii, Borrelia burgdorferi, Anaplasma phagocytophylum, R. felis, R. helvetica, R. conorii subsp. conorii strain Malish, R. africae, R. sibirica mongolotimonae, R. massiliae, and R. slovaca, as previously described (3). A case of symptomatic confirmed ATBF was defined as clinical illness and positive serologic results against R. africae, whereas a case of probable ATBF was defined as typical clinical symptoms without definite serologic evidence of R. africae infection. Table Epidemiologic, clinical, and serologic information for 10 patients with African tick-bite fever* Of the 34 travelers, 30 completed the questionnaire and 20 consented to give at least 1 serum sample. After their return to France, symptoms compatible clinically with ATBF developed in 10 of the travelers (Table) and 9 had positive serologic results and/or a seroconversion for spotted fever group-rickettsia, including R. africae (Table). The median time from illness onset to serum testing was 19 days. Thus, 9 of the travelers had probable and 1 had possible (no serum was available) ATBF. Including both probable and possible cases, the illness rate for the whole group was 33.3% (10/30). None of the travelers reported a history of tick bite. The delay between probable exposure and onset of symptoms was 3-10 days (mean ± standard deviation 6.1 ± 1.9 days). Multiple eschars on the legs or arms were seen in 7 (70%) of 10 patients. Eight patients received doxycycline (200 mg per day) for a mean of 10.8 ± 5.9 days (range 5-20), 1 patient received pristinamycin for 8 days, and 1 patient received no treatment. All patients recovered fully without sequela; however, 6 patients reported convalescent-phase asthenia and 1 reported chronic insomnia, which had not occurred previously, for 2 months after the illness. Among the 10 remaining travelers, for whom a serum sample was available, with no clinical evidence of ATBF, 5 were positive for R. africae with only immunoglobulin M (IgM) at a titer of 1:32 in 4 cases and IgG at 1:128 with IgM at 1:32 in 1 case (an acute-phase serum from this patient showed IgG at 1:32 and IgM at 1:32). The 5 other travelers had negative serologic results. Results of serologic testing for other bacteria were negative for all travelers. Twenty-four travelers (80%), including the 10 symptomatic patients, reported using topical insect repellent daily. Most cases of ATBF are reported in clusters of travelers exposed to ticks during game hunting or safaris, as described here (1,3-5). The estimated incidence of African tick-bite fever in safari travelers is 4%-5.3% (4) but higher incidence may be reported as emphasized in our study. In our study, epidemiologic and clinical data for the 10 symptomatic patients were obtained in accordance with current knowledge of ATBF (2). Skin biopsy samples remain the best tool to isolate or detect R. africae (2,6). However, specific serologic tests, especially immunofluorescence assays, remain the most widely used microbiologic test worldwide (7). No commercially available test for ATBF exists but due to extensive cross-reactions between spotted fever group rickettsiosis, commercial kits based on the detection of R. conorii antibodies can be used for the diagnosis of ATBF. Most tourists reported using topical insect repellents without any efficacy. Applying repellents to exposed skin provides little protection against ticks because they can crawl underneath clothing and bite untreated portions of the body (8). Thus, treating clothing with synthetic pyrethroid insecticide is recommended to complement the topical repellant (8). In conclusion, our study emphasizes the importance of ATBF as a common cause of flulike illness in travelers returning from South Africa, but with a higher rate than malaria, typhoid fever, or other tropical fevers. The most important clinical clues are the presence of clustered cases with multiple inoculation eschars. Healthcare professionals who are providing advice should inform persons traveling to endemic areas of Africa of the risk of contracting ATBF and the importance of protecting themselves against tick bites. Chemoprophylaxis with doxycycline is not recommended, however, this recommendation may be evaluated in future clinical trials.

Rickettsial diseases

<h2>Abstract</h2> Rickettsial diseases are transmitted by arthropod vectors and are responsible for various spotted and typhus fevers. Epidemic typhus fever (Rickettsia prowazekii) occurs in prisons, in refugee camps and during wars, when lice thrive in unhygienic, overcrowded conditions. Endemic typhus (R. typhi) arises when humans live close to flea-infested rodents, typically near granaries, breweries, shops and garbage tips. Spotted fever infections are contracted by humans in the rural habitat of the tick or mite vector and include Rocky Mountain (R. rickettsiae), Scrub typhus (Orientia tsutsugamushi), Mediterranean (R. conorrii) and African tick-bite (R. africae) fever. Spotted fevers are characterized by an eschar (black scab) at the site of the arthropod bite. A petechial or purpuric skin rash accompanies typhus and spotted fevers, though 10% of Rocky Mountain spotted fever and almost all cases of African tick-bite fever are ‘spotless'. Other features are headache, night sweats, lymphadenopathy and conjunctivitis. Vasculitic complications include gangrenous extremities, bowel perforation, liver dysfunction, renal failure, meningoencephalitis, disseminated intravascular coagulation and pneumonia. Laboratory diagnosis is by demonstration of seroconversion on paired samples using immunofluorescence assay. Tetracyclines are the mainstay of treatment. Children, pregnant women and those allergic to tetracyclines can be treated with chloramphenicol or newer macrolides. There are currently no vaccines against rickettsial diseases. Avoidance of the insect vector using protective clothing and topical repellents is recommended. Mortality may approach 10–25% in epidemic typhus and scrub typhus, but is lower (2–5%) in Mediterranean spotted fever and murine typhus.

Outbreak of African Tick-Bite Fever in Six Italian Tourists Returning from South Africa

In May 1999, a cluster of cases of African tick-bite fever was detected in six Italian tourists who had returned from South Africa. All of the patients had moderate fever and cutaneous eschars. Regional lymphangitis was observed in three of the patients and skin rash in two. By comparing the number of eschars with the number of detectable bite sites it was suggested that at least two-thirds of the biting vectors were capable of transmitting Rickettsia africae. The clinical course of disease was mild in all cases, and all but one of the patients recovered spontaneously before antibiotic treatment was initiated. The diagnosis of African tick-bite fever was confirmed serologically using both microimmunofluorescence and Western blot tests.